KALA BIO (KALA) to Release Quarterly Earnings on Friday

KALA BIO (NASDAQ:KALA) is projected to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($2.28) per share for the quarter.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings data on Monday, March 31st. The company reported ($1.74) EPS for the quarter, topping analysts’ consensus estimates of ($2.28) by $0.54. On average, analysts expect KALA BIO to post $-11 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

KALA BIO Price Performance

Shares of NASDAQ:KALA opened at $5.73 on Wednesday. The firm has a market capitalization of $34.90 million, a PE ratio of -0.46 and a beta of -2.19. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18. KALA BIO has a 1-year low of $4.21 and a 1-year high of $11.20. The business’s 50 day moving average is $7.63 and its 200-day moving average is $6.81.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of KALA BIO in a report on Thursday, February 13th.

Insiders Place Their Bets

In other news, CEO Mark T. Iwicki sold 5,779 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $44,093.77. Following the sale, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. This represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold a total of 9,506 shares of company stock worth $72,531 over the last quarter. Company insiders own 8.32% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.